Armata Pharmaceuticals (ARMP) vs Anavex Life Sciences (AVXL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Armata Pharmaceuticals (ARMP) has outperformed Anavex Life Sciences (AVXL) over the past year, gaining 13.1% versus a loss of 84.3%. Over five years, ARMP leads with a +5.2% price change compared with -91.5% for AVXL. Anavex Life Sciences is the larger company by market cap ($138.1 million vs $135.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARMP | AVXL |
|---|---|---|
| Share price | $3.63 | $1.49 |
| Market cap | $134.97M | $138.12M |
| 1-day change | -5.96% | -3.25% |
| YTD return | -42.20% | -58.15% |
| 1-year return | +13.08% | -84.35% |
| 5-year return | +5.22% | -91.50% |
| EPS (TTM) | $-4.97 | $-0.14 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $16.34 | $9.50 |
| 52-week low | $3.14 | $1.44 |
| Distance from 52-week high | -77.78% | -84.32% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +382.09% | — |
| Average volume | 208.13K | 983.35K |
| Shares outstanding | 37.18M | 92.70M |
| Employees | 61 | 34 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ARMP has outperformed AVXL by 97.4 percentage points over the past year.
About Armata Pharmaceuticals
ARMP stock →Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 61 employees
About Anavex Life Sciences
AVXL stock →Anavex Life Sciences Corp. operates as a biopharmaceutical company.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 34 employees
ARMP vs AVXL FAQ
Which is bigger, Armata Pharmaceuticals or Anavex Life Sciences?
Anavex Life Sciences (AVXL) is larger, with a market capitalization of $138.12M compared with $134.97M for Armata Pharmaceuticals (ARMP).
Which stock has performed better over the past year, ARMP or AVXL?
ARMP returned +13.08% over the past 12 months, compared with -84.35% for AVXL (price return, excluding dividends). Past performance does not predict future results.
Are Armata Pharmaceuticals and Anavex Life Sciences in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.